Syndax Pharmaceuticals, Inc

(NASDAQ:SNDX)

Latest On Syndax Pharmaceuticals, Inc (SNDX):

Date/Time Type Description Signal Details
2023-05-09 04:24 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.59 beats by $0.01N/A
2023-05-09 04:24 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call TranscriptN/A
2023-05-08 02:38 ESTNewsSyndax Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-04 02:40 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 16:35 ESTNewsSyndax Pharmaceuticals: 2023 Is A Pivotal YearN/A
2023-03-01 01:25 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.62 beats by $0.04N/A
2023-02-27 19:50 ESTNewsSyndax Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-12 14:22 ESTNewsSyndax Pharmaceuticals (SNDX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowN/A
2022-12-17 03:56 ESTNewsSyndax Pharmaceuticals (SNDX) Presents at 64th ASH Annual Meeting & ExpositionN/A
2022-12-12 19:48 ESTNewsKura Oncology falls, Syndax gains after Phase 1/2 data for leukemia candidatesN/A
2022-12-10 16:27 ESTNewsSyndax Pharmaceuticals: Today's Best Nearby Biotech Cap-Gain ProspectN/A
2022-12-07 20:58 ESTNewsSyndax Pharmaceuticals prices $150M offeringN/A
2022-12-07 01:27 ESTNewsSyndax Pharma to sell $150M stock in public offeringN/A
2022-12-05 14:27 ESTNewsSyndax receives breakthrough therapy tag for revumenib to treat acute leukemiaN/A
2022-11-06 14:31 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q3 2022 Earnings Call TranscriptN/A
2022-11-06 14:31 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-04 08:33 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.58 beats by $0.07; updates FY22 guidanceN/A
2022-11-02 23:19 ESTNewsSyndax Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.62N/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-08 07:37 ESTNewsSyndax Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-13 12:56 ESTNewsKeith Goldan joins Syndax Pharmaceuticals as CFON/A
2022-05-10 14:01 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-10 14:01 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-09 16:51 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.63N/A
2022-05-09 00:26 ESTNewsSyndax Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-08 05:11 ESTNewsSyndax Pharmaceuticals: Cash-Rich With 2 Promising DrugsN/A
2022-03-25 00:25 ESTNewsSyndax Pharmaceuticals (SNDX) Presents At Barclays Global Healthcare ConferenceN/A
2022-03-02 06:49 ESTNewsSyndax appoints former Alnylam executive as new medical chiefN/A
2022-03-02 06:49 ESTNewsSyndax Pharmaceuticals GAAP EPS of $1.81 beats by $1.84, revenue of $126.6M beats by $67.92MN/A
2022-03-02 06:48 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-28 18:56 ESTNewsSyndax Pharmaceuticals Q4 Earnings PreviewN/A
2022-01-29 06:36 ESTNewsSyndax Pharmaceuticals (SNDX) Investor Presentation - SlideshowN/A
2021-12-23 00:22 ESTNewsSyndax's SNDX-5613 an Orphan Drug in Europe for acute myeloid leukemiaN/A
2021-12-16 14:02 ESTNewsSyndax Pharma raises $75M via stock offeringN/A
2021-12-15 18:28 ESTNewsSyndax Pharmaceuticals drops 6% following underwritten stock offeringN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals EPS misses by $0.35, misses on revenueN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-14 18:13 ESTNewsSyndax Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-11-04 16:35 ESTNewsSyndax Pharma falls after updating early-stage data for leukemia therapyN/A
2021-10-05 15:59 ESTNewsSyndax Pharma CFO Daphne Karydas to resign to pursue another opportunityN/A
2021-09-28 02:06 ESTNewsIncyte and Syndax in pact for xatilimab targeting immune-related conditionsN/A
2021-08-10 12:01 ESTNewsSyndax Pharmaceuticals EPS beats by $0.28, beats on revenueN/A
2021-08-10 12:00 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-10 11:59 ESTNewsSyndax Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-07-22 02:04 ESTNewsSyndax Pharmaceuticals: Updated Analysis After Reporting Interim Phase 1 DataN/A
2021-07-22 02:02 ESTNewsCanopy upgraded on economy reopening, Xeris PT cut on acquisition news, and more in analyst actionN/A
2021-07-22 01:35 ESTNewsSyndax shares rise on FDA Fast Track status for leukemia treatment SNDX-5613N/A

About Syndax Pharmaceuticals, Inc (SNDX):

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

See Advanced Chart

General

  • Name Syndax Pharmaceuticals, Inc
  • Symbol SNDX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 43
  • Fiscal Year EndDecember
  • IPO Date2016-03-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.syndax.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 634.74
  • Price/Book (Most Recent Quarter) 4.43
  • Enterprise Value Revenue 542.55
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.19
  • Next Year EPS Estimate -$2.17
  • Next Quarter EPS Estimate -$0.47
  • Operating Margin -4708%
  • Return on Assets -25%
  • Return on Equity -52%
  • Revenue 1.52 million
  • Earnings Per Share -$2.36
  • Revenue Per Share $0.04
  • Gross Profit 1.52 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.16 billion
  • EBITDA -67280000
  • PE Ratio -125.39
  • Analyst Target Price $32.14
  • Book Value Per Share $5.27
View More

Share Statistics

  • Shares Outstanding 48.24 million
  • Shares Float 42.95 million
  • % Held by Insiders 645%
  • % Held by Institutions 78.88%
  • Shares Short 4.93 million
  • Shares Short Prior Month 4.93 million
  • Short Ratio 9.27
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.84
  • 52 Week High $27.12
  • 52 Week Low $8.18
  • 50 Day Moving Average 22.33
  • 200 Day Moving Average 20.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Syndax Pharmaceuticals, Inc (SNDX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Syndax Pharmaceuticals, Inc (SNDX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-08$380000-$0.44-$0.5113.23%
2020-09-302020-11-02$N/A-$0.46-$0.43-6.75%
2020-06-302020-08-06$N/A-$0.42-$0.444.76%
2020-03-312020-05-07$379000-$0.56-$0.53-6.65%
2019-12-312020-03-03$380000-$0.44-$0.43-1.31%
2019-09-302019-11-07$379000-$0.41-$0.4813.92%
2019-06-302019-08-07$379000-$0.47-$0.470.76%
2019-03-312019-05-06$379000-$0.53-$0.554.14%
2018-12-312019-03-07$379000-$0.70-$0.64-9.43%
2018-09-302018-11-05$379000-$0.68-$0.7610.21%
2018-06-302018-08-07$379000-$0.74-$0.8916.94%
2018-03-312018-05-08$379000-$0.79-$0.9517.15%
2017-12-312018-03-05$1.19 million-$0.80-$0.77-3.67%
2017-09-302017-11-07$305000-$0.68-$0.8216.63%
2017-06-302017-08-10$305000-$0.70-$0.8214.83%
2017-03-312017-05-08$305000-$0.71-$0.710.56%
2016-12-312017-03-02$305000-$0.59-$0.7419.79%
2016-09-302016-11-10$305000-$0.84-$0.82-2.78%
2016-06-302016-08-09$305000-$0.47-$0.5412.18%
2016-03-312016-05-16$305000-$0.73-$0.48-52.22%

Syndax Pharmaceuticals, Inc (SNDX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Syndax Pharmaceuticals, Inc (SNDX) Chart:

Syndax Pharmaceuticals, Inc (SNDX) News:

Below you will find a list of latest news for Syndax Pharmaceuticals, Inc (SNDX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Syndax Pharmaceuticals, Inc (SNDX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-09-1910CALL0 0595.29TRUE00
2025-09-192.50CALL0 01339.38TRUE00
2025-09-1940CALL0 0280.06TRUE00
2025-09-1950CALL0 0404.89TRUE00
2025-09-1960CALL0 0281.81TRUE00
2025-09-197.58.5CALL0 1224.59TRUE00
2025-09-1990CALL0 0217.7TRUE00
2025-09-19105.33CALL0 21164.25TRUE00
2025-09-19110CALL0 0121.48TRUE00
2025-09-1912.52.85CALL0 3972.29TRUE00
2025-09-19142.8CALL0 140673.83TRUE00
2025-09-19151.72CALL4 86770.78TRUE0.230.15
2025-09-19161.2CALL29 25370.16FALSE1.20
2025-09-1917.50.61CALL32 959466.98FALSE-0.34-0.36
2025-09-19190.45CALL0 183.5FALSE00
2025-09-19200.45CALL0 101073.75FALSE00
2025-09-19210CALL0 0182.16FALSE00
2025-09-19220.2CALL0 14111.22FALSE00
2025-09-19230.15CALL0 8183.61FALSE00
2025-09-19240CALL0 0188.74FALSE00
2025-09-19250CALL0 0209.07FALSE00
2025-09-1910PUT0 0947.02FALSE00
2025-09-192.50PUT0 0558.11FALSE00
2025-09-1940PUT0 0871.67FALSE00
2025-09-1950PUT0 0348.82FALSE00
2025-09-1960PUT0 0299FALSE00
2025-09-197.50.35PUT0 2126.93FALSE00
2025-09-1990PUT0 0191.79FALSE00
2025-09-19100.05PUT0 1060137.84FALSE00
2025-09-19110.1PUT0 20141.43FALSE00
2025-09-1912.50.3PUT0 185101.65FALSE00
2025-09-19140.5PUT0 76059.61FALSE00
2025-09-19150.8PUT125 24168.91FALSE-0.1-0.11
2025-09-19160PUT0 072.46TRUE00
2025-09-1917.52.65PUT0 282.4TRUE00
2025-09-19190PUT0 068.14TRUE00
2025-09-19205.1PUT0 177.49TRUE00
2025-09-19210PUT0 0142.85TRUE00
2025-09-19227.61PUT0 10150.95TRUE00
2025-09-19230PUT0 0128.74TRUE00
2025-09-19240PUT0 0124.5TRUE00
2025-09-19250PUT0 0158.25TRUE00
2025-10-1710CALL0 00TRUE00
2025-10-172.50CALL0 0689.51TRUE00
2025-10-1740CALL0 0323.56TRUE00
2025-10-17510.5CALL0 13203.61TRUE00
2025-10-1760CALL0 0239.36TRUE00
2025-10-177.57.15CALL0 21175.38TRUE00
2025-10-1790CALL0 0157.58TRUE00
2025-10-17106.21CALL0 51782.8TRUE00
2025-10-17110CALL0 0111.35TRUE00
2025-10-1712.53.85CALL0 71477.93TRUE00
2025-10-17142.95CALL1 1978.03TRUE2.950
2025-10-17152.25CALL15 616871.97TRUE-0.15-0.06
2025-10-17161.65CALL0 1454.05FALSE00
2025-10-1717.51.25CALL49 15973.72FALSE0.050.04
2025-10-17191.05CALL0 1064.9FALSE00
2025-10-17200.7CALL1 23476.46FALSE0.10.17
2025-10-17210.6CALL0 795.56FALSE00
2025-10-1722.50.05CALL0 272.5FALSE00
2025-10-17240CALL0 0131.77FALSE00
2025-10-17250.24CALL0 334373.46FALSE00
2025-10-17300CALL0 0121.48FALSE00
2025-10-1710PUT0 00FALSE00
2025-10-172.50PUT0 0509.39FALSE00
2025-10-1740PUT0 0294.64FALSE00
2025-10-1750.75PUT0 2249.44FALSE00
2025-10-1760PUT0 0213.89FALSE00
2025-10-177.50.2PUT0 351217.54FALSE00
2025-10-1790PUT0 0137.41FALSE00
2025-10-17100.15PUT100 110284.06FALSE00
2025-10-17110.75PUT0 3127.54FALSE00
2025-10-1712.51.15PUT0 282979.47FALSE00
2025-10-17141.1PUT0 1479.59FALSE00
2025-10-17152.05PUT0 59056.48FALSE00
2025-10-17160PUT0 045.7TRUE00
2025-10-1717.52.83PUT0 13178.68TRUE00
2025-10-17190PUT0 089.18TRUE00
2025-10-17200PUT0 083.63TRUE00
2025-10-17210PUT0 068.51TRUE00
2025-10-1722.50PUT0 0125.16TRUE00
2025-10-17240PUT0 0117.17TRUE00
2025-10-17250PUT0 077.21TRUE00
2025-10-17300PUT0 0100.11TRUE00
2026-01-162.50CALL0 1199.45TRUE00
2026-01-1655.13CALL0 13133.69TRUE00
2026-01-167.58.65CALL0 14776.66TRUE00
2026-01-1690CALL0 085.25TRUE00
2026-01-16106.3CALL0 86985.04TRUE00
2026-01-16116CALL0 482.49TRUE00
2026-01-1612.55.1CALL10 718185.21TRUE0.070.01
2026-01-16142.2CALL0 4483.5TRUE00
2026-01-16153.5CALL0 137182.57TRUE00
2026-01-16163.36CALL0 2677.88FALSE00
2026-01-1617.52.7CALL30 75180.37FALSE2.70
2026-01-16201.99CALL0 41279.53FALSE00
2026-01-1622.51.1CALL0 10174.02FALSE00
2026-01-16251.18CALL0 52165.09FALSE00
2026-01-16300.75CALL0 9185.45FALSE00
2026-01-16350.4CALL0 18084FALSE00
2026-01-162.50PUT0 0159.37FALSE00
2026-01-1650.36PUT0 8158.48FALSE00
2026-01-167.50.05PUT0 5100.09FALSE00
2026-01-1690PUT0 081.73FALSE00
2026-01-16100.75PUT0 6884.29FALSE00
2026-01-16110.97PUT0 483.5FALSE00
2026-01-1612.51.45PUT0 166384.29FALSE00
2026-01-16142.24PUT0 163.97FALSE00
2026-01-16152.67PUT0 26082.03FALSE00
2026-01-16160PUT0 080.9TRUE00
2026-01-1617.54PUT12 18078.07TRUE40
2026-01-16200PUT0 081.55TRUE00
2026-01-1622.50PUT0 675.82TRUE00
2026-01-16250PUT0 094.4TRUE00
2026-01-16300PUT0 0111.72TRUE00
2026-01-16350PUT0 0100.84TRUE00
2026-04-1750CALL0 0131.69TRUE00
2026-04-1760CALL0 0104.65TRUE00
2026-04-1777.8CALL0 1133.11TRUE00
2026-04-1780CALL0 0112.99TRUE00
2026-04-1790CALL0 088.09TRUE00
2026-04-17100CALL0 077.34TRUE00
2026-04-17110CALL0 084.35TRUE00
2026-04-17120CALL0 069.55TRUE00
2026-04-17130CALL0 082.05TRUE00
2026-04-17140CALL0 076.74TRUE00
2026-04-17154.23CALL0 2371.12TRUE00
2026-04-17163.8CALL0 4074.38FALSE00
2026-04-17170CALL0 073.64FALSE00
2026-04-17180CALL0 077.66FALSE00
2026-04-17190CALL0 072.16FALSE00
2026-04-17202.61CALL0 175.91FALSE00
2026-04-17210CALL0 071.79FALSE00
2026-04-17250CALL0 062.54FALSE00
2026-04-17300CALL0 078.91FALSE00
2026-04-1750PUT0 0251.66FALSE00
2026-04-1760PUT0 0213.06FALSE00
2026-04-1770PUT0 090.27FALSE00
2026-04-1780PUT0 098.82FALSE00
2026-04-1790PUT0 087.98FALSE00
2026-04-17100PUT0 070.95FALSE00
2026-04-17110PUT0 067.44FALSE00
2026-04-17120PUT0 080.17FALSE00
2026-04-17130PUT0 072FALSE00
2026-04-17140PUT0 071.86FALSE00
2026-04-17150PUT0 066.95FALSE00
2026-04-17160PUT0 083.64TRUE00
2026-04-17170PUT0 075.43TRUE00
2026-04-17180PUT0 073.31TRUE00
2026-04-17190PUT0 078.43TRUE00
2026-04-17200PUT0 077.06TRUE00
2026-04-17210PUT0 074.14TRUE00
2026-04-17250PUT0 084.45TRUE00
2026-04-17300PUT0 095.77TRUE00

Latest SNDX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST3$15.6
Jun 13, 2022 7:59 PM EST4$15.6
Jun 13, 2022 7:59 PM EST1$15.6
Jun 13, 2022 7:59 PM EST100$15.61
Jun 13, 2022 7:59 PM EST45$15.61

Syndax Pharmaceuticals, Inc (SNDX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020028764/0001564590-20-028764-index.htm
2019-09-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1395937/000000000019013216/0000000000-19-013216-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000021545719006549/0000215457-19-006549-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000083423720006818/0000834237-20-006818-index.htm
2020-09-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000083423720010194/0000834237-20-010194-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090221919000254/0000902219-19-000254-index.htm
2020-01-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090221920000308/0000902219-20-000308-index.htm
2019-04-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090266419001816/0000902664-19-001816-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090266420000971/0000902664-20-000971-index.htm
2020-11-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000091957420006675/0000919574-20-006675-index.htm
2018-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000092189518001976/0000921895-18-001976-index.htm
2018-11-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189518003173/0000921895-18-003173-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189519000467/0000921895-19-000467-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189520000574/0000921895-20-000574-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000101359419000160/0001013594-19-000160-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000101359420000127/0001013594-20-000127-index.htm
2018-04-10DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000114036118018005/0001140361-18-018005-index.htm
2018-04-10DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1395937/000114036118018007/0001140361-18-018007-index.htm
2018-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312518197997/0001193125-18-197997-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312519034379/0001193125-19-034379-index.htm
2019-03-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519088951/0001193125-19-088951-index.htm
2019-03-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312519092679/0001193125-19-092679-index.htm
2019-03-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519092701/0001193125-19-092701-index.htm
2019-08-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1395937/000119312519235283/0001193125-19-235283-index.htm
2019-09-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1395937/000119312519239953/0001193125-19-239953-index.htm
2019-09-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519242045/0001193125-19-242045-index.htm
2019-10-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312519265254/0001193125-19-265254-index.htm
2020-02-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312520022917/0001193125-20-022917-index.htm
2020-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312520023646/0001193125-20-023646-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312520037637/0001193125-20-037637-index.htm
2020-05-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312520139263/0001193125-20-139263-index.htm
2018-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002680/0001562180-18-002680-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002681/0001562180-18-002681-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002682/0001562180-18-002682-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002683/0001562180-18-002683-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002684/0001562180-18-002684-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002685/0001562180-18-002685-index.htm
2018-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004047/0001562180-18-004047-index.htm
2018-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004048/0001562180-18-004048-index.htm
2018-09-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004049/0001562180-18-004049-index.htm
2018-09-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004050/0001562180-18-004050-index.htm
2018-11-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/0001562180-18-004443-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000852/0001562180-19-000852-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000853/0001562180-19-000853-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000854/0001562180-19-000854-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000855/0001562180-19-000855-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000856/0001562180-19-000856-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2019-03-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002023/0001562180-19-002023-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003487/0001562180-19-003487-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003488/0001562180-19-003488-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003489/0001562180-19-003489-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003490/0001562180-19-003490-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003491/0001562180-19-003491-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003492/0001562180-19-003492-index.htm
2019-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003880/0001562180-19-003880-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019005140/0001562180-19-005140-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020000891/0001562180-20-000891-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001228/0001562180-20-001228-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001229/0001562180-20-001229-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001230/0001562180-20-001230-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001231/0001562180-20-001231-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001232/0001562180-20-001232-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001233/0001562180-20-001233-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001234/0001562180-20-001234-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001235/0001562180-20-001235-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001236/0001562180-20-001236-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001237/0001562180-20-001237-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001238/0001562180-20-001238-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/0001562180-20-005074-index.htm
2020-07-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020005102/0001562180-20-005102-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2018-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018004520/0001564590-18-004520-index.htm
2018-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459018004911/0001564590-18-004911-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018011784/0001564590-18-011784-index.htm
2018-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/0001564590-18-012378-index.htm
2018-05-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018014349/0001564590-18-014349-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018019907/0001564590-18-019907-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018020483/0001564590-18-020483-index.htm
2018-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459018020504/0001564590-18-020504-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018023593/0001564590-18-023593-index.htm
2018-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018026817/0001564590-18-026817-index.htm
2018-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018026892/0001564590-18-026892-index.htm
2019-02-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019002676/0001564590-19-002676-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/0001564590-19-006772-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019006777/0001564590-19-006777-index.htm
2019-03-1810-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459019008313/0001564590-19-008313-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000156459019014263/0001564590-19-014263-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019015972/0001564590-19-015972-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019017318/0001564590-19-017318-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019022241/0001564590-19-022241-index.htm
2019-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019024625/0001564590-19-024625-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019030050/0001564590-19-030050-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019030067/0001564590-19-030067-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459019030084/0001564590-19-030084-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019036518/0001564590-19-036518-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019041712/0001564590-19-041712-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019041719/0001564590-19-041719-index.htm
2019-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019045581/0001564590-19-045581-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020004037/0001564590-20-004037-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020005551/0001564590-20-005551-index.htm
2020-03-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020008426/0001564590-20-008426-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459020009016/0001564590-20-009016-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000156459020019694/0001564590-20-019694-index.htm
2020-04-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020019928/0001564590-20-019928-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020019941/0001564590-20-019941-index.htm
2020-05-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020020574/0001564590-20-020574-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020020633/0001564590-20-020633-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020022849/0001564590-20-022849-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020022971/0001564590-20-022971-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020028764/0001564590-20-028764-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020031882/0001564590-20-031882-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020037719/0001564590-20-037719-index.htm
2020-08-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459020037767/0001564590-20-037767-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020037777/0001564590-20-037777-index.htm
2020-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020049638/0001564590-20-049638-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020051287/0001564590-20-051287-index.htm
2019-09-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1395937/999999999519002056/9999999995-19-002056-index.htm
2018-11-27CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999716026189/9999999997-16-026189-index.htm
2018-04-03CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718004150/9999999997-18-004150-index.htm
2018-06-13CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718006372/9999999997-18-006372-index.htm
2018-08-29CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718007508/9999999997-18-007508-index.htm
2018-12-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718009113/9999999997-18-009113-index.htm
2019-03-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999719002097/9999999997-19-002097-index.htm

Syndax Pharmaceuticals, Inc (SNDX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Syndax Pharmaceuticals, Inc (SNDX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 645%
Institutional Ownership: 7888%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-04-03Peter OrdentlichChief Scientific OfficerSell7,500.0015.00112,500.000.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm
2020-07-06Michael L. MeyersSVP, Chief Medical OfficerBuy3,500.0010,730.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/0001562180-20-005074-index.htm
2020-11-04Michael A MetzgerPresident and COOBuy100,000.007.20720,000.00117,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2019-05-09Briggs MorrisonChief Executive OfficerBuy13,200.007.5699,726.0013,200.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2020-02-12Michael A MetzgerPresident and COOBuy15,000.0017,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020001238/0001562180-20-001238-index.htm
2020-11-04Michael A MetzgerPresident and COOSell100,000.0020.312,031,410.0017,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2019-05-13Briggs MorrisonChief Executive OfficerBuy7,200.007.2952,516.8020,400.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2018-10-30Michael L. MeyersSVP, Chief Medical OfficerBuy200.004.79958.002,398.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/0001562180-18-004443-index.htm
2019-10-10Briggs MorrisonChief Executive OfficerBuy11,000.005.4059,400.0031,400.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019005140/0001562180-19-005140-index.htm
2020-02-04Briggs MorrisonChief Executive OfficerBuy12,500.008.00100,000.0043,900.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020000891/0001562180-20-000891-index.htm
2019-03-21Michael L. MeyersSVP, Chief Medical OfficerBuy1,000.004.934,930.007,118.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2019-03-21Michael L. MeyersSVP, Chief Medical OfficerBuy104.004.87506.487,222.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2018-04-03Peter OrdentlichChief Scientific OfficerBuy7,500.003.0823,100.007,500.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm